



上海源叶生物科技有限公司
Shanghai yuanye Bio-Technology Co., Ltd
电话: 021-61312973 传真: 021-55068248
网址: www.shyuanye.com
邮箱: shyyssw@sina.com

产品名称: **GNF-2**
CAS 号: **778270-11-4**
产品货号: **S86486**

生物活性:				
Description	GNF-2 是一种具有高度选择性、变构的、非 ATP 竞争性 Bcr-Abl 抑制剂。 GNF-2 抑制 Ba/F3.p210 增殖, IC50 为 138 nM。			
IC50 & Target	Bcr-Abl[1]			
Cellular Effect	Cell Line	Type	Value	Description
	BaF3	IC ₅₀	> 10 μ M	Antiproliferative activity against mouse BA/F3 Bcr-abl negative cells expressing Flt3-ITD kinase assessed as proliferation after 48 hrs by MTT assay
	BaF3	IC ₅₀	> 10 μ M	Antiproliferative activity against mouse BA/F3 Bcr-abl negative cells expressing Tel-PDGFRbeta kinase assessed as proliferation after 48 hrs by MTT assay
	BaF3	IC ₅₀	> 10 μ M	Antiproliferative activity against mouse BA/F3 Bcr-abl negative cells expressing TPR-MET kinase assessed as proliferation after 48 hrs by MTT assay
	BaF3	IC ₅₀	> 10 μ M	Antiproliferative activity against mouse BA/F3 Bcr-abl negative cells expressing Tel-JAK1 kinase assessed as proliferation after 48 hrs by MTT assay
	BaF3	IC ₅₀	> 10000 nM	Antiproliferation activity against mouse BA/F3 cells expressing Bcr-abl A337N mutant assessed as cell viability after 48 hrs by MTT assay
	BaF3	IC ₅₀	138 nM	Antiproliferation activity against mouse BA/F3 cells expressing Bcr-abl assessed as cell viability after 48 hrs by MTT assay
	BaF3	IC ₅₀	2367 nM	Antiproliferation activity against mouse BA/F3 cells expressing Bcr-abl A334I mutant assessed as cell viability after 48 hrs by MTT assay
	HL-60	IC ₅₀	> 10 μ M	Antiproliferative activity against human HL60 Bcr-abl negative cells assessed as cell viability after 48 hrs by MTT assay
	Jurkat	IC ₅₀	> 10 μ M	Antiproliferative activity against human Jurkat Bcr-abl negative cells assessed as proliferation after 48 hrs by MTT assay
	K562	IC ₅₀	0.273 μ M	Antiproliferative activity against human K562 expressing Bcr-abl assessed as proliferation after 48 hrs by MTT assay
	SUP-B15	IC ₅₀	0.268 μ M	Antiproliferative activity against human SUP-B15 expressing Bcr-abl assessed as proliferation after 48 hrs by MTT assay
In Vitro	GNF-2 选择性地抑制 Bcr-abl 依赖性细胞增殖。 GNF-2 (0.005-10 μ M; 48 小时) 特异性抑制			



	Bcr-abl 表达细胞的增殖, IC50 为 138 nM, 并且在一定浓度下对未转化细胞没有任何细胞毒性作用高达 10 μM。GNF-2 (0.005-10 μM; 48 小时) 对 Bcr-abl 阳性细胞系产生剂量依赖性生长抑制, IC50 值为 273 nM (K562) 和 268 nM (SUP -B15)。GNF-2 (0.005-10 μM; 48 小时) 抑制 E255V 和 Y253H 突变型 Bcr-abl 细胞生长 (IC50 值分别为 268 和 194 nM)[1]。 GNF-2 (1-10 μM; 48 hours) 诱导 Bcr-abl 转化细胞的凋亡[1]。 GNF-2 (0.1-10 μM; 90 分钟) 以剂量依赖性方式抑制 Bcr-abl 的细胞酪氨酸磷酸化, IC50 为 267 nM[1]。 Cell Proliferation Assay[1] <table><tr><td>Cell Line:</td><td>Ba/F3.p210, Ba/F3.p210^{E255V} and Ba/F3.p185^{Y253H} cells</td></tr><tr><td>Concentration:</td><td>0.005, 0.01, 0.1, 1, 10μM</td></tr><tr><td>Incubation Time:</td><td>48 hours</td></tr><tr><td>Result:</td><td>Inhibited Bcr-abl-transformed cells proliferation.</td></tr></table> Apoptosis Analysis[1] <table><tr><td>Cell Line:</td><td>Ba/F3.p210 and Ba/F3.p210^{E255V} cells</td></tr><tr><td>Concentration:</td><td>1, 10μM</td></tr><tr><td>Incubation Time:</td><td>48 hours</td></tr><tr><td>Result:</td><td>Increased number of Ba/F3.p210 cells undergoing apoptosis at 1μM for 48 h. Ba/F3.p210E255V underwent apoptotic death after 48 h incubation in the presence of 1μM or higher concentration.</td></tr></table> Western Blot Analysis[1] <table><tr><td>Cell Line:</td><td>Ba/F3.p210 and Ba/F3.p210^{E255V} cells</td></tr><tr><td>Concentration:</td><td>0.1, 1, 10μM</td></tr><tr><td>Incubation Time:</td><td>90 minutes</td></tr><tr><td>Result:</td><td>Decreased the autophosphorylation levels at a concentration of 1μM and were barely detectable at 10μM, whereas the level of total Bcr-abl remained unchanged. Induced a significant decrease in the levels of p-Stat5 (at Y694) at 1μM in Ba/F3.p210 and Ba/F3.p210E255V cells.</td></tr></table>	Cell Line:	Ba/F3.p210, Ba/F3.p210 ^{E255V} and Ba/F3.p185 ^{Y253H} cells	Concentration:	0.005, 0.01, 0.1, 1, 10 μ M	Incubation Time:	48 hours	Result:	Inhibited Bcr-abl-transformed cells proliferation.	Cell Line:	Ba/F3.p210 and Ba/F3.p210 ^{E255V} cells	Concentration:	1, 10 μ M	Incubation Time:	48 hours	Result:	Increased number of Ba/F3.p210 cells undergoing apoptosis at 1 μ M for 48 h. Ba/F3.p210E255V underwent apoptotic death after 48 h incubation in the presence of 1 μ M or higher concentration.	Cell Line:	Ba/F3.p210 and Ba/F3.p210 ^{E255V} cells	Concentration:	0.1, 1, 10 μ M	Incubation Time:	90 minutes	Result:	Decreased the autophosphorylation levels at a concentration of 1 μ M and were barely detectable at 10 μ M, whereas the level of total Bcr-abl remained unchanged. Induced a significant decrease in the levels of p-Stat5 (at Y694) at 1 μ M in Ba/F3.p210 and Ba/F3.p210E255V cells.
Cell Line:	Ba/F3.p210, Ba/F3.p210 ^{E255V} and Ba/F3.p185 ^{Y253H} cells																								
Concentration:	0.005, 0.01, 0.1, 1, 10 μ M																								
Incubation Time:	48 hours																								
Result:	Inhibited Bcr-abl-transformed cells proliferation.																								
Cell Line:	Ba/F3.p210 and Ba/F3.p210 ^{E255V} cells																								
Concentration:	1, 10 μ M																								
Incubation Time:	48 hours																								
Result:	Increased number of Ba/F3.p210 cells undergoing apoptosis at 1 μ M for 48 h. Ba/F3.p210E255V underwent apoptotic death after 48 h incubation in the presence of 1 μ M or higher concentration.																								
Cell Line:	Ba/F3.p210 and Ba/F3.p210 ^{E255V} cells																								
Concentration:	0.1, 1, 10 μ M																								
Incubation Time:	90 minutes																								
Result:	Decreased the autophosphorylation levels at a concentration of 1 μ M and were barely detectable at 10 μ M, whereas the level of total Bcr-abl remained unchanged. Induced a significant decrease in the levels of p-Stat5 (at Y694) at 1 μ M in Ba/F3.p210 and Ba/F3.p210E255V cells.																								
In Vivo	GNF-2 (10 mg/kg; 腹腔注射 8 天) 保护 LPS (5 mg/kg) 诱导的小鼠骨侵蚀。GNF-2 保护 LPS 诱导的骨丢失, 并消除 LPS 诱导的 LPS 处理小鼠的骨体积/组织体积 (BV/TV) 减少[2]。 GNF-2 防止 LPS 引起的 N. Oc/B. Pm、Oc.S/BS 百分比和 ES/BS 百分比增加[2]。 <table><tr><td>Animal Model:</td><td>Eight-week-old C57/BL6 mice were administered i.p. injections of LPS (5 mg/kg)[2]</td></tr><tr><td>Dosage:</td><td>10 mg/kg</td></tr><tr><td>Administration:</td><td>I.p. injections for 8 days; 1 day before and every day after the LPS injection</td></tr><tr><td>Result:</td><td>Prevented inflammatory bone destruction in vivo</td></tr></table>	Animal Model:	Eight-week-old C57/BL6 mice were administered i.p. injections of LPS (5 mg/kg)[2]	Dosage:	10 mg/kg	Administration:	I.p. injections for 8 days; 1 day before and every day after the LPS injection	Result:	Prevented inflammatory bone destruction in vivo																
Animal Model:	Eight-week-old C57/BL6 mice were administered i.p. injections of LPS (5 mg/kg)[2]																								
Dosage:	10 mg/kg																								
Administration:	I.p. injections for 8 days; 1 day before and every day after the LPS injection																								
Result:	Prevented inflammatory bone destruction in vivo																								
Solvent&Solubility	细胞实验: DMSO 中的溶解度 : ≥ 100 mg/mL (267.15 mM; 吸湿的 DMSO 对产品的溶解度有显著影响, 请使用新开封的 DMSO) H2O 中的溶解度 : < 0.1 mg/mL (insoluble)																								



	* "≥" means soluble, but saturation unknown				
Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg	
	1 mM	2.6715 mL	13.3577 mL	26.7154 mL	
	5 mM	0.5343 mL	2.6715 mL	5.3431 mL	
	10 mM	0.2672 mL	1.3358 mL	2.6715 mL	
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80℃, 2 years; -20℃, 1 year。-80℃ 储存时，请在 2 年内使用， -20℃ 储存时，请在 1 年内使用。 动物实验： 请根据您的 实验动物和给药方式 选择适当的溶解方案。 以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂： ——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶 方案 一 请依序添加每种溶剂： 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% Saline Solubility: ≥ 2.5 mg/mL (6.68 mM); 澄清溶液 此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。 以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水 定容至 1 mL。 生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。 方案 二 请依序添加每种溶剂： 10% DMSO → 90% (20% SBE-β-CD in Saline) Solubility: ≥ 2.5 mg/mL (6.68 mM); 澄清溶液 此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。 以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水电溶液 中，混合均匀。 2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。 方案 三 请依序添加每种溶剂： 10% DMSO → 90% Corn Oil Solubility: ≥ 2.5 mg/mL (6.68 mM); 澄清溶液 此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。 以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 玉米油中，混合均匀。					
参考文献	[1]. Adrián FJ, et al. Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat Chem Biol. 2006 Feb;2(2):95-102. [2]. Kim HJ, et al. The tyrosine kinase inhibitor GNF-2 suppresses osteoclast formation and activity. J Leukoc Biol. 2013 Oct 15 .				



上海源叶生物科技有限公司
Shanghai yuanye Bio-Technology Co., Ltd
电话: 021-61312973 传真: 021-55068248
网址: www.shyuanye.com
邮箱: shyyssw@sina.com

完整储备液配制表:

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。

储备液的保存方式和期限: -80° C, 2 years; -20° C, 1 year。-80° C 储存时,请在 2 年内使用, -20° C 储存时,请在 1 年内使用。

可选溶剂	质量 溶剂体积 浓度	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.6715 mL	13.3577 mL	26.7154 mL	66.7884 mL
	5 mM	0.5343 mL	2.6715 mL	5.3431 mL	13.3577 mL
	10 mM	0.2672 mL	1.3358 mL	2.6715 mL	6.6788 mL
	15 mM	0.1781 mL	0.8905 mL	1.7810 mL	4.4526 mL
	20 mM	0.1336 mL	0.6679 mL	1.3358 mL	3.3394 mL
	25 mM	0.1069 mL	0.5343 mL	1.0686 mL	2.6715 mL
	30 mM	0.0891 mL	0.4453 mL	0.8905 mL	2.2263 mL
	40 mM	0.0668 mL	0.3339 mL	0.6679 mL	1.6697 mL
	50 mM	0.0534 mL	0.2672 mL	0.5343 mL	1.3358 mL
	60 mM	0.0445 mL	0.2226 mL	0.4453 mL	1.1131 mL
	80 mM	0.0334 mL	0.1670 mL	0.3339 mL	0.8349 mL
	100 mM	0.0267 mL	0.1336 mL	0.2672 mL	0.6679 mL